{
    "clinical_study": {
        "@rank": "61971", 
        "arm_group": [
            {
                "arm_group_label": "Normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single and multiple dose of normal saline"
            }, 
            {
                "arm_group_label": "Single dose IV of biapenem or RPX7009", 
                "arm_group_type": "Experimental", 
                "description": "Single dose IV infusion of biapenem or RPX7009"
            }, 
            {
                "arm_group_label": "Single dose of biapenem or RPX7009", 
                "arm_group_type": "Experimental", 
                "description": "Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)"
            }, 
            {
                "arm_group_label": "Biapenem and RPX7009 in combination", 
                "arm_group_type": "Experimental", 
                "description": "Single dose followed by a multiple dose of biapenem and RPX7009 in combination"
            }
        ], 
        "brief_summary": {
            "textblock": "RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem\n      biapenem to treat bacterial infections, including those due to multi-drug resistant\n      bacteria."
        }, 
        "brief_title": "Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Bacterial Infections"
        ], 
        "condition_browse": {
            "mesh_term": "Bacterial Infections"
        }, 
        "detailed_description": {
            "textblock": "The worldwide spread of resistance to antibiotics among Gram-negative bacteria, particularly\n      members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of\n      hospital acquired infections. In particular, the recent dissemination of a serine\n      carbapenemase (e.g., KPC) in Enterobacteriaceae in US hospitals now poses a considerable\n      threat to the carbapenems and other members of the beta-lactam class of antimicrobial\n      agents.\n\n      Rempex is developing a fixed combination antibiotic of a carbapenem (RPX2003 or biapenem)\n      plus a new beta-lactamase inhibitor (RPX7009) which has activity against serine\n      beta-lactamases, including KPC. This Phase 1 study will assess the safety, tolerability and\n      pharmacokinetics and pharmacodynamics of Intravenous Biapenem and RPX7009, administered\n      alone and in combination in healthy adult subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult males and/or females, 18 to 55 years of age\n\n          -  Body mass index (BMI) \u2265 18.5 and \u2264 29.9 (kg/m2) and weight between 55.0 and     100.0\n             kg (inclusive).\n\n          -  Medically healthy with clinically insignificant screening results\n\n          -  Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day\n             1.\n\n          -  Sexually abstinent or use acceptable methods of birth control\n\n        Exclusion Criteria:\n\n          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,\n             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,\n             or psychiatric disease.\n\n          -  History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.\n\n          -  Hypersensitivity or idiosyncratic reaction to beta-lactam antibiotics (e.g.\n             penicillins, cephalosporins, carbapenems, etc.).\n\n          -  Use of any over-the-counter (OTC) medication, including herbal products and vitamins,\n             within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed\n             for acute events at the discretion of the PI.\n\n          -  Plasma donation within 7 days prior to Day 1.\n\n          -  Subjects who have any abnormalities on laboratory values at screening or check-in\n             (Day -1)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772836", 
            "org_study_id": "Rempex 403"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Single dose IV of biapenem or RPX7009", 
                    "Single dose of biapenem or RPX7009", 
                    "Biapenem and RPX7009 in combination"
                ], 
                "description": "Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)", 
                "intervention_name": "RPX7009", 
                "intervention_type": "Drug", 
                "other_name": "(beta-lactamase inhibitor)"
            }, 
            {
                "arm_group_label": [
                    "Single dose IV of biapenem or RPX7009", 
                    "Single dose of biapenem or RPX7009", 
                    "Biapenem and RPX7009 in combination"
                ], 
                "description": "Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)", 
                "intervention_name": "Biapenem", 
                "intervention_type": "Drug", 
                "other_name": "RPX2003"
            }, 
            {
                "arm_group_label": "Normal saline", 
                "description": "Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Biapenem"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Adelaide", 
                    "country": "Australia", 
                    "state": "South Australia", 
                    "zip": "5000"
                }, 
                "name": "CMAX"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination in Healthy Adult Subjects.", 
        "overall_official": {
            "affiliation": "Sponsor GmbH", 
            "last_name": "Jefferey Loutit, MBChB", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.", 
            "measure": "Safety from baseline to the end of the study", 
            "safety_issue": "No", 
            "time_frame": "Day 1 - Day 17"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772836"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparison will be performed between the cohorts for the plasma AUC0-t, AUC0-inf, Cmax, and Tmax.\nUrine PK parameters such as amount excreted and % dose excreted will be calculated from urinary excretion data.", 
                "measure": "Composite of Pharmacokinetic (PK) parameters of RPX7009, biapenem & the combination following ascending single and multiple dose administration.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 - Day 14"
            }, 
            {
                "description": "Serum for bactericidal titers (SBT) assessments will be collected on Days 1, 4, 7 and 14 (at the end-of-infusion (EOI)), and at 2, 4, and 8 hours after start of infusion.", 
                "measure": "Composite of Pharmacodynamic (PD) parameters of RPX7009, biapenem & the combination following ascending single and multiple dose administration.", 
                "safety_issue": "No", 
                "time_frame": "Days 1-14"
            }
        ], 
        "source": "Rempex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rempex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}